nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—Acetylsalicylic acid—Kawasaki disease	0.29	0.436	CbGbCtD
Erlotinib—CYP2C8—Acetylsalicylic acid—Kawasaki disease	0.224	0.337	CbGbCtD
Erlotinib—ABCB1—Acetylsalicylic acid—Kawasaki disease	0.151	0.228	CbGbCtD
Erlotinib—Vandetanib—BLK—Kawasaki disease	0.0152	0.653	CrCbGaD
Erlotinib—Foetor hepaticus—Acetylsalicylic acid—Kawasaki disease	0.0124	0.103	CcSEcCtD
Erlotinib—Peptic ulcer—Acetylsalicylic acid—Kawasaki disease	0.0105	0.0877	CcSEcCtD
Erlotinib—Liver disorder—Acetylsalicylic acid—Kawasaki disease	0.0103	0.086	CcSEcCtD
Erlotinib—Haematemesis—Acetylsalicylic acid—Kawasaki disease	0.0101	0.0843	CcSEcCtD
Erlotinib—Hepatotoxicity—Acetylsalicylic acid—Kawasaki disease	0.00913	0.0759	CcSEcCtD
Erlotinib—AURKC—heart—Kawasaki disease	0.00822	0.0492	CbGeAlD
Erlotinib—Vandetanib—VEGFA—Kawasaki disease	0.00809	0.347	CrCbGaD
Erlotinib—ULK3—cardiac ventricle—Kawasaki disease	0.00789	0.0472	CbGeAlD
Erlotinib—PIP4K2C—myocardium—Kawasaki disease	0.00777	0.0465	CbGeAlD
Erlotinib—JAK3—heart—Kawasaki disease	0.00761	0.0456	CbGeAlD
Erlotinib—MKNK1—cardiac ventricle—Kawasaki disease	0.00742	0.0444	CbGeAlD
Erlotinib—ULK3—myocardium—Kawasaki disease	0.00742	0.0444	CbGeAlD
Erlotinib—Hepatocellular injury—Acetylsalicylic acid—Kawasaki disease	0.00705	0.0586	CcSEcCtD
Erlotinib—SLK—cardiac ventricle—Kawasaki disease	0.00703	0.0421	CbGeAlD
Erlotinib—TNK1—heart—Kawasaki disease	0.00699	0.0418	CbGeAlD
Erlotinib—MKNK1—myocardium—Kawasaki disease	0.00698	0.0418	CbGeAlD
Erlotinib—Melaena—Acetylsalicylic acid—Kawasaki disease	0.00688	0.0572	CcSEcCtD
Erlotinib—SLK—myocardium—Kawasaki disease	0.00661	0.0396	CbGeAlD
Erlotinib—FLT3—heart—Kawasaki disease	0.006	0.0359	CbGeAlD
Erlotinib—ORM1—gall bladder—Kawasaki disease	0.00579	0.0347	CbGeAlD
Erlotinib—ABL2—heart—Kawasaki disease	0.00573	0.0343	CbGeAlD
Erlotinib—EGFR—heart—Kawasaki disease	0.0056	0.0335	CbGeAlD
Erlotinib—PIP4K2C—heart—Kawasaki disease	0.00542	0.0325	CbGeAlD
Erlotinib—Renal impairment—Acetylsalicylic acid—Kawasaki disease	0.00538	0.0447	CcSEcCtD
Erlotinib—ULK3—heart—Kawasaki disease	0.00518	0.031	CbGeAlD
Erlotinib—MAP2K5—myocardium—Kawasaki disease	0.00514	0.0307	CbGeAlD
Erlotinib—Gastrointestinal haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.00512	0.0425	CcSEcCtD
Erlotinib—ALB—gall bladder—Kawasaki disease	0.00508	0.0304	CbGeAlD
Erlotinib—MKNK1—heart—Kawasaki disease	0.00487	0.0292	CbGeAlD
Erlotinib—Hypokalaemia—Acetylsalicylic acid—Kawasaki disease	0.00466	0.0387	CcSEcCtD
Erlotinib—SLK—heart—Kawasaki disease	0.00462	0.0276	CbGeAlD
Erlotinib—ABL1—cardiac ventricle—Kawasaki disease	0.00421	0.0252	CbGeAlD
Erlotinib—STK10—heart—Kawasaki disease	0.00401	0.024	CbGeAlD
Erlotinib—ABL1—myocardium—Kawasaki disease	0.00396	0.0237	CbGeAlD
Erlotinib—MAP2K5—heart—Kawasaki disease	0.00358	0.0215	CbGeAlD
Erlotinib—Haemoglobin—Acetylsalicylic acid—Kawasaki disease	0.00356	0.0296	CcSEcCtD
Erlotinib—Haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.00354	0.0294	CcSEcCtD
Erlotinib—SLCO2B1—heart—Kawasaki disease	0.00279	0.0167	CbGeAlD
Erlotinib—TNK1—Focal Adhesion—ITGAE—Kawasaki disease	0.00277	0.113	CbGpPWpGaD
Erlotinib—ABL1—heart—Kawasaki disease	0.00277	0.0166	CbGeAlD
Erlotinib—Syncope—Acetylsalicylic acid—Kawasaki disease	0.00276	0.023	CcSEcCtD
Erlotinib—ABL1—skin of body—Kawasaki disease	0.00271	0.0162	CbGeAlD
Erlotinib—Loss of consciousness—Acetylsalicylic acid—Kawasaki disease	0.00271	0.0225	CcSEcCtD
Erlotinib—Chest pain—Acetylsalicylic acid—Kawasaki disease	0.00262	0.0218	CcSEcCtD
Erlotinib—Arthralgia—Acetylsalicylic acid—Kawasaki disease	0.00262	0.0218	CcSEcCtD
Erlotinib—ALB—heart—Kawasaki disease	0.00255	0.0153	CbGeAlD
Erlotinib—CYP1A1—cardiac ventricle—Kawasaki disease	0.00252	0.0151	CbGeAlD
Erlotinib—Shock—Acetylsalicylic acid—Kawasaki disease	0.00247	0.0206	CcSEcCtD
Erlotinib—Thrombocytopenia—Acetylsalicylic acid—Kawasaki disease	0.00246	0.0205	CcSEcCtD
Erlotinib—CYP1B1—heart—Kawasaki disease	0.00234	0.014	CbGeAlD
Erlotinib—CYP1B1—skin of body—Kawasaki disease	0.00229	0.0137	CbGeAlD
Erlotinib—Dyspnoea—Acetylsalicylic acid—Kawasaki disease	0.00224	0.0186	CcSEcCtD
Erlotinib—Dyspepsia—Acetylsalicylic acid—Kawasaki disease	0.00221	0.0184	CcSEcCtD
Erlotinib—EPHA6—EPHA forward signaling—BLK—Kawasaki disease	0.00195	0.0798	CbGpPWpGaD
Erlotinib—Pruritus—Acetylsalicylic acid—Kawasaki disease	0.00178	0.0148	CcSEcCtD
Erlotinib—ABCG2—heart—Kawasaki disease	0.00174	0.0104	CbGeAlD
Erlotinib—Diarrhoea—Acetylsalicylic acid—Kawasaki disease	0.00172	0.0143	CcSEcCtD
Erlotinib—Dizziness—Acetylsalicylic acid—Kawasaki disease	0.00166	0.0138	CcSEcCtD
Erlotinib—CYP1A1—heart—Kawasaki disease	0.00166	0.00991	CbGeAlD
Erlotinib—CYP1A1—skin of body—Kawasaki disease	0.00162	0.00971	CbGeAlD
Erlotinib—Vomiting—Acetylsalicylic acid—Kawasaki disease	0.0016	0.0133	CcSEcCtD
Erlotinib—Rash—Acetylsalicylic acid—Kawasaki disease	0.00159	0.0132	CcSEcCtD
Erlotinib—Dermatitis—Acetylsalicylic acid—Kawasaki disease	0.00158	0.0132	CcSEcCtD
Erlotinib—Nausea—Acetylsalicylic acid—Kawasaki disease	0.00149	0.0124	CcSEcCtD
Erlotinib—TNK1—Focal Adhesion—BLK—Kawasaki disease	0.00147	0.0601	CbGpPWpGaD
Erlotinib—JAK3—CD40/CD40L signaling—CD40—Kawasaki disease	0.00124	0.0506	CbGpPWpGaD
Erlotinib—MAP2K5—Integrin-mediated Cell Adhesion—ITGAE—Kawasaki disease	0.00101	0.0412	CbGpPWpGaD
Erlotinib—ABCB1—heart—Kawasaki disease	0.00086	0.00515	CbGeAlD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—ITPKC—Kawasaki disease	0.000753	0.0307	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—ITPKC—Kawasaki disease	0.000643	0.0263	CbGpPWpGaD
Erlotinib—JAK3—IL4-mediated signaling events—IL10—Kawasaki disease	0.000615	0.0251	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—ITGAE—Kawasaki disease	0.000604	0.0247	CbGpPWpGaD
Erlotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—FCGR2A—Kawasaki disease	0.000545	0.0222	CbGpPWpGaD
Erlotinib—EPHA6—EPHA-mediated growth cone collapse—VEGFA—Kawasaki disease	0.00054	0.022	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by PTP1B—FCGR2A—Kawasaki disease	0.000501	0.0205	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by PTP1B—BLK—Kawasaki disease	0.000486	0.0198	CbGpPWpGaD
Erlotinib—EGFR—Thromboxane A2 receptor signaling—BLK—Kawasaki disease	0.000458	0.0187	CbGpPWpGaD
Erlotinib—EPHA6—EPH-ephrin mediated repulsion of cells—MMP9—Kawasaki disease	0.000456	0.0186	CbGpPWpGaD
Erlotinib—TNK1—Focal Adhesion—VEGFA—Kawasaki disease	0.000417	0.017	CbGpPWpGaD
Erlotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—FCGR2A—Kawasaki disease	0.000411	0.0168	CbGpPWpGaD
Erlotinib—JAK3—Signaling events mediated by TCPTP—VEGFA—Kawasaki disease	0.000388	0.0158	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—ITGAE—Kawasaki disease	0.000324	0.0132	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—BLK—Kawasaki disease	0.000321	0.0131	CbGpPWpGaD
Erlotinib—JAK3—SHP2 signaling—VEGFA—Kawasaki disease	0.000288	0.0118	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—BLK—Kawasaki disease	0.000282	0.0115	CbGpPWpGaD
Erlotinib—EPHA6—EPH-Ephrin signaling—MMP9—Kawasaki disease	0.000266	0.0109	CbGpPWpGaD
Erlotinib—JAK3—Oncostatin M Signaling Pathway—VEGFA—Kawasaki disease	0.000263	0.0107	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—FCGR2A—Kawasaki disease	0.00026	0.0106	CbGpPWpGaD
Erlotinib—EPHA6—EPH-Ephrin signaling—VEGFA—Kawasaki disease	0.000239	0.00977	CbGpPWpGaD
Erlotinib—EGFR—Bladder Cancer—VEGFA—Kawasaki disease	0.000208	0.00849	CbGpPWpGaD
Erlotinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—Kawasaki disease	0.000182	0.00741	CbGpPWpGaD
Erlotinib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—Kawasaki disease	0.00018	0.00736	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—BLK—Kawasaki disease	0.000172	0.00703	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by TCPTP—VEGFA—Kawasaki disease	0.00017	0.00692	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—BLK—Kawasaki disease	0.000169	0.00689	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	0.000156	0.00635	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—CRP—Kawasaki disease	0.000152	0.00621	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	0.000152	0.00619	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—CD40—Kawasaki disease	0.000146	0.00595	CbGpPWpGaD
Erlotinib—EGFR—LPA receptor mediated events—MMP9—Kawasaki disease	0.00013	0.00529	CbGpPWpGaD
Erlotinib—EGFR—AGE/RAGE pathway—MMP9—Kawasaki disease	0.000127	0.00516	CbGpPWpGaD
Erlotinib—EGFR—SHP2 signaling—VEGFA—Kawasaki disease	0.000126	0.00514	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—CRP—Kawasaki disease	0.000124	0.00506	CbGpPWpGaD
Erlotinib—ABL2—Axon guidance—MMP9—Kawasaki disease	0.000117	0.00479	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL10—Kawasaki disease	0.000112	0.00456	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ITPKC—Kawasaki disease	0.000109	0.00445	CbGpPWpGaD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	0.000106	0.00433	CbGpPWpGaD
Erlotinib—ABL2—Axon guidance—VEGFA—Kawasaki disease	0.000105	0.0043	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ITPKC—Kawasaki disease	0.000102	0.00415	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—MMP9—Kawasaki disease	9.9e-05	0.00404	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	9.88e-05	0.00403	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—CRP—Kawasaki disease	9.84e-05	0.00402	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FCGR2A—Kawasaki disease	9.73e-05	0.00397	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	9.58e-05	0.00391	CbGpPWpGaD
Erlotinib—JAK3—Immune System—BLK—Kawasaki disease	9.44e-05	0.00385	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ITPKC—Kawasaki disease	9.26e-05	0.00378	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—VEGFA—Kawasaki disease	9.09e-05	0.00371	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—VEGFA—Kawasaki disease	8.89e-05	0.00363	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FCGR2A—Kawasaki disease	8.55e-05	0.00349	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—MMP9—Kawasaki disease	8.38e-05	0.00342	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—MMP9—Kawasaki disease	7.95e-05	0.00324	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD40—Kawasaki disease	7.84e-05	0.0032	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—VEGFA—Kawasaki disease	7.52e-05	0.00307	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FCGR2A—Kawasaki disease	7.31e-05	0.00298	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—MMP9—Kawasaki disease	7.07e-05	0.00288	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—MMP9—Kawasaki disease	6.89e-05	0.00281	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—VEGFA—Kawasaki disease	6.86e-05	0.0028	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—BLK—Kawasaki disease	6.81e-05	0.00278	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CCR5—Kawasaki disease	6.66e-05	0.00272	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ITPKC—Kawasaki disease	6.63e-05	0.00271	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CCR5—Kawasaki disease	6.55e-05	0.00267	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—VEGFA—Kawasaki disease	6.35e-05	0.00259	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ITPKC—Kawasaki disease	6.27e-05	0.00256	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	6.11e-05	0.00249	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCR5—Kawasaki disease	5.95e-05	0.00243	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—Kawasaki disease	5.86e-05	0.00239	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ITPKC—Kawasaki disease	5.74e-05	0.00234	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	5.73e-05	0.00234	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ITPKC—Kawasaki disease	5.71e-05	0.00233	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	5.68e-05	0.00232	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD40—Kawasaki disease	5.66e-05	0.00231	CbGpPWpGaD
Erlotinib—ALB—Platelet degranulation—VEGFA—Kawasaki disease	5.61e-05	0.00229	CbGpPWpGaD
Erlotinib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—Kawasaki disease	5.35e-05	0.00218	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—VEGFA—Kawasaki disease	5.09e-05	0.00208	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CRP—Kawasaki disease	5.05e-05	0.00206	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ITPKC—Kawasaki disease	5e-05	0.00204	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FCGR2A—Kawasaki disease	4.98e-05	0.00203	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—VEGFA—Kawasaki disease	4.97e-05	0.00203	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—VEGFA—Kawasaki disease	4.88e-05	0.00199	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	4.86e-05	0.00198	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BLK—Kawasaki disease	4.83e-05	0.00197	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ITPKC—Kawasaki disease	4.72e-05	0.00192	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCR5—Kawasaki disease	4.66e-05	0.0019	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CRP—Kawasaki disease	4.44e-05	0.00181	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FCGR2A—Kawasaki disease	4.26e-05	0.00174	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—Kawasaki disease	4.18e-05	0.00171	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP9—Kawasaki disease	4.15e-05	0.00169	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BLK—Kawasaki disease	4.13e-05	0.00168	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD40—Kawasaki disease	4.01e-05	0.00164	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ITPKC—Kawasaki disease	3.99e-05	0.00163	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CRP—Kawasaki disease	3.8e-05	0.00155	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—Kawasaki disease	3.72e-05	0.00152	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—Kawasaki disease	3.54e-05	0.00145	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCR5—Kawasaki disease	3.51e-05	0.00143	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD40—Kawasaki disease	3.43e-05	0.0014	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—Kawasaki disease	3.41e-05	0.00139	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—Kawasaki disease	3.18e-05	0.0013	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ITPKC—Kawasaki disease	3.08e-05	0.00126	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—Kawasaki disease	3e-05	0.00122	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—Kawasaki disease	2.96e-05	0.00121	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR5—Kawasaki disease	2.87e-05	0.00117	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—Kawasaki disease	2.66e-05	0.00108	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—Kawasaki disease	2.61e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR5—Kawasaki disease	2.6e-05	0.00106	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CRP—Kawasaki disease	2.59e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—Kawasaki disease	2.56e-05	0.00105	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—Kawasaki disease	2.55e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—Kawasaki disease	2.53e-05	0.00103	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	2.49e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—Kawasaki disease	2.46e-05	0.001	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	2.45e-05	0.001	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—Kawasaki disease	2.29e-05	0.000934	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—Kawasaki disease	2.27e-05	0.000926	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CRP—Kawasaki disease	2.21e-05	0.000902	CbGpPWpGaD
Erlotinib—EGFR—Disease—CCR5—Kawasaki disease	2.2e-05	0.000896	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—Kawasaki disease	1.92e-05	0.000784	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—Kawasaki disease	1.75e-05	0.000713	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—Kawasaki disease	1.73e-05	0.000704	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—Kawasaki disease	1.57e-05	0.000639	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR5—Kawasaki disease	1.54e-05	0.000627	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—Kawasaki disease	1.49e-05	0.000609	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—Kawasaki disease	1.41e-05	0.000574	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—Kawasaki disease	1.38e-05	0.000563	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—Kawasaki disease	1.28e-05	0.000524	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—Kawasaki disease	8.41e-06	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—Kawasaki disease	7.55e-06	0.000308	CbGpPWpGaD
